Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FMmeds vs RestorLife Med

FMmeds
Graded #257

Lower grade

vs+2.0999999999999943
RestorLife Med
Graded #222

Higher grade

The verdict

RestorLife Med takes it — 65.3/100 to 63.2/100.

RestorLife Med grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. RestorLife Med is a physician-guided GLP-1 telehealth practice (founder Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFMmeds +2
46
44
Dose & formulationFMmeds +20
72
52
Clinical oversightRestorLife Med +27
70
97
Labs & monitoringRestorLife Med +13
53
66
FulfillmentEven
97
97
Contract termsFMmeds +10
47
37
FMmeds · left barRestorLife Med · right bar

The numbers

MetricFMmedsRestorLife Med
WeighScore63.2/10065.3/100
GradeCC
Scorecard rank#257#222
Semaglutide$225/mo (all doses, compounded)$199/mo (6-month plan, compounded)
Tirzepatide$265/mo (all doses, compounded)Not disclosed
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
FMmeds

Graded #257 · C

Strengths

  • All 50 states plus DC covered, stated in the Terms
  • Operating LLC and full Manhattan Beach, CA address disclosed
  • Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
  • Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
  • Flat pricing across all dose strengths — no dose-escalation surcharge

Where it loses points

  • Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
  • Clinical network not separately named
  • LegitScript Certified, but the specific ID isn't shown
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
RestorLife Med

Graded #222 · C

Strengths

  • Verifiable LegitScript certification (seal ID 50400451) plus a named board-certified physician (Dr. Michael Wasef, MD) licensed in all 50 states
  • Full GLP-1 lineup: compounded semaglutide and tirzepatide, plus gentler microdose entry options
  • Generous support — unlimited care-team messaging, monthly check-ins, dosage adjustments, and 1 free blood test per quarter on the GLP-1 protocols
  • Available in all 50 states with free priority shipping, discreet packaging, and roughly 48-hour delivery
  • Transparent multi-month pricing with 50% off your first month; semaglutide protocols are compounded with B12

Where it loses points

  • The advertised $299 is a struck-through anchor price, not a starting point: the real month-to-month rate is $299, a first month runs $149 at 50% off, and the $199 rate needs six months
  • The page states its pricing is 'introductory and subject to change', so none of these figures is committed to
  • The tirzepatide price is published the same way, against a struck-through anchor, and we could not establish which figure a buyer actually pays
  • A separate semaglutide microdose is sold at $99/mo — a sub-therapeutic protocol, not a cheaper weight-loss dose
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard